Anupriya Chhabra

About

I am a Postdoctoral Fellow at Johns Hopkins University, Baltimore, USA, specializing in Nuclear Medicine and Radiopharmaceutical Sciences. I completed my Ph.D. at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. My current research is focused on Alpha-radiopharmaceutical therapy (RPT), specifically working with Actinium-225 for cancer treatment. I have extensive experience in in vitro radioligand assays, preclinical studies, and the development of theranostic agents.

Employment

• Johns Hopkins University Postdoctoral Fellow
  2023 - Present
• Thomas Jefferson University Postdoctoral Fellow
  2021 - 2023
• Postgraduate Institute of Medical Education and Resrarch Ph.D.
  2016 - 2020

Education

• Post Graduate Institute of Medical Education and Research Ph.D.
  2016 - 2020
• Post Graduate Institute of Medical Education and Research MSc
  2013 - 2015

Projects & Funding

Projects & funding information is unavailable.

Publications (17)

• MRI detects tubulointerstitial changes in mouse models of radiation-induced nephropathy
  Magnetic Resonance in Medicine 2025 DOI: 10.1002/mrm.30443
  +Save
• Quality Considerations in Radiopharmaceuticals
  Targeted Radiopharmaceuticals and Imaging 2025 DOI: 10.1039/9781837677139-00435
  +Save
• Enhanced activity localization and microscale dosimetry in alpha-emitter radiopharmaceutical therapy using integrated autoradiography and histological imaging
  Scientific Reports 2025 DOI: 10.1038/s41598-025-09277-4
  +Save
• Comparison of 99mTc-methylenediphosphonate and 68Ga-BPAMD PET/computed tomography imaging in bone metastasis
  Nuclear Medicine Communications 2023 DOI: 10.1097/MNM.0000000000001685
  +Save
• Cold kit for Rhenium-188 microspheres based selective intra-arterial therapy (SIRT): Preparation, characterization and feasibility study.
  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2022 DOI: 10.1016/j.apradiso.2022.110423
  +Save
• Tc-99m-tamoxifen: A novel diagnostic imaging agent for estrogen receptor-expressing breast cancer patients.
  Diagnostic and interventional radiology (Ankara, Turkey) 2022 DOI: 10.5152/dir.2022.201051
  +Save
• Nuclear medicine in the management of superficial skin abnormalities and institutional experience.
  Nuclear medicine communications 2022 DOI: 10.1097/mnm.0000000000001549
  +Save
• Theragnostic Radionuclide Pairs for Prostate Cancer Management: 64Cu/67Cu, Can Be a Budding Hot Duo
  Biomedicines 2022 DOI: 10.3390/biomedicines10112787
  +Save
• Re-188-tricarbonyl tamoxifen as a theranostic radiopharmaceutical for estrogen receptor expressing breast cancers: radiolabeling, characterization and in-vitro cytotoxic assessment.
  Nuclear medicine communications 2021 DOI: 10.1097/mnm.0000000000001402
  +Save
• Development of 68Ga DOTA-CRH for PET/CT Imaging of ACTH-Dependent Cushing's Disease: Initial Study.
  Cancer biotherapy & radiopharmaceuticals 2021 DOI: 10.1089/cbr.2020.4686
  +Save